Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: Prognostic value in adults with early-stage disease

Timothy R. Sterling, Donald R. Hoover, Jacquie Astemborski, David Vlahov, John G. Bartlett, Jorg Schupbach

Research output: Contribution to journalArticlepeer-review

Abstract

CD4+ lymphocyte count and human immunodeficiency virus (HIV) type 1 RNA level are useful for determining when to initiate antiretroviral therapy but are not used widely in developing countries due to the high cost. Heat-denatured protein 24 (p24) antigen is an inexpensive assay that predicts disease progression among persons with advanced disease but has not been assessed among persons with early-stage disease. Plasma levels of heat-denatured p24 antigen were quantified in baseline study-visit specimens obtained from injection drug users enrolled in a longitudinal cohort study of HIV-1 infection. Of the 494 study participants (median initial CD4+ lymphocyte count, 518 lymphocytes/mm3), 90 (18%) progressed to acquired immunodeficiency syndrome within 5 years. p24 antigen level correlated with both CD4+ lymphocyte count (r = -0.34; P< .0001) and HIV-1 RNA level (r = 0.55; P< .0001). p24 antigen level >5 pg/mL predicted disease progression, comparable with that of cutoff CD4+ lymphocyte count <350 lymphocytes/mm3 and HIV-1 RNA level >30,000 copies/mL. Heat-denatured p24 antigen level predicted subsequent clinical disease progression in early-stage HIV-1 infection and correlated with both CD4+ lymphocyte count and HIV-1 RNA level.

Original languageEnglish (US)
Pages (from-to)1181-1185
Number of pages5
JournalJournal of Infectious Diseases
Volume186
Issue number8
DOIs
StatePublished - Oct 15 2002

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: Prognostic value in adults with early-stage disease'. Together they form a unique fingerprint.

Cite this